Advanced Flower Capital Inc. (AFCG) Market Cap
Advanced Flower Capital Inc. has a market capitalization of $65.4M.
Financials based on reported quarter end 2025-12-31
Price: $2.78
▲ 0.08 (2.96%)
Market Cap: 65.41M
NASDAQ · time unavailable
CEO: Daniel Neville
Sector: Real Estate
Industry: REIT - Specialty
IPO Date: 2021-03-19
Website: https://advancedflowercapital.com
Advanced Flower Capital Inc. (AFCG) - Company Information
Market Cap: 65.41M · Sector: Real Estate
Advanced Flower Capital, Inc. provides commercial real estate finance services. It primarily engages in originating, structuring, underwriting and managing senior secured loans and other types of loans for established companies operating in the cannabis industry in states. The company was founded by Leonard Mark Tannenbaum on July 6, 2020 and is headquartered in West Palm Beach, FL.
Analyst Sentiment
Based on 2 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 3 sources)
Consensus Price Target
Low
$10
Median
$13
High
$25
Average
$16
Potential Upside: 475.5%
Price & Moving Averages
Related Companies in Real Estate
FRANKLIN STREET PROPERTIES REIT CO (FSP)
Real Estate
$0.07B
Mkt Cap
LUMENT FINANCE TRUST INC (LFT)
Real Estate
$0.07B
Mkt Cap
CLIPPER REALTY INC (CLPR)
Real Estate
$0.05B
Mkt Cap
MOBILE INFRASTRUCTURE CORP (BEEP)
Real Estate
$0.09B
Mkt Cap
SUNRISE REALTY TRUST INC (SUNS)
Real Estate
$0.11B
Mkt Cap
RITHM PROPERTY INC TRUST (RPT)
Real Estate
$0.11B
Mkt Cap
Management’s tone is cautiously constructive: they emphasize BDC conversion (completed 01/01/2026), strong pipeline scale (active pipeline cited at $1.4B vs $0.4B prior quarter), and early 2026 wins ($60M Stat/Morsby facility and a $30M healthcare benefits commitment). However, the Q&A pressure highlights material operational bottlenecks that can delay earnings conversion. Distributions from legacy estates are slow (Private Company A: $6.8M distributed in 2025; $6.4M pending in front of the receiver; pace “frustrated”), and Private Company K sales are dependent on regulatory timing (CCC approval typically 3–4 months). Justice Grown provides little incremental visibility beyond the 05/01/2026 maturity and an appeal ruling expected “in the coming months.” Critically, management also admits a ~$100M/quarter deployment pace is not currently sustainable due to cash and credit-facility capacity. Net: upside exists via BDC flexibility, but near-term income durability remains hostage to legal/regulatory timelines and legacy credit resolution.
Growth Catalysts
- Conversion from REIT to BDC (completed 01/01/2026) expanded investable universe beyond real-estate coverage restrictions and beyond cannabis-only constraints
- Portfolio paydowns redeployable into performing credits: $117,000,000 received from performing + underperforming credits since start of 2025 through call date
- Early 2026 BDC deal momentum: $60,000,000 senior secured credit facility (Stat + Morsby) and $30,000,000 commitment ($20,000,000 funded at closing) for a healthcare benefits platform
Business Development
- Stat (revenue recovery specialist) + Morsby Group acquisition/financing; sponsor: Cambridge Capital; facility size $60,000,000 senior secured
- Healthcare benefits platform tailored to hourly and sub-$50,000 salaried employees; sponsor noted as top-tier (not named); $30,000,000 senior secured term loan commitment (funded $20,000,000 at closing)
Financial Highlights
- Q4 2025 distributable earnings: -$2,800,000 (-$0.12 per basic weighted average share); GAAP net income: $900,000 ($0.04 per share)
- Full-year 2025 distributable earnings: $8,700,000 ($0.39 per share); GAAP net loss: -$20,700,000 (-$0.95 per share)
- Dividend classification: 2025 dividends characterized as return of capital and tax-free due to realized losses from two underperforming credits; future dividends may be similar if additional 2026 realized losses occur
- Declared Q1 dividend: $0.05 per share; paid 04/15/2026; record date 03/31/2026
- Net interest income: $5,200,000 for quarter; $24,600,000 for full year
- Balance sheet/credit metrics: ended 2025 with CECL reserve $46.1M (~18.2% of loans at carrying value); total unrealized loss on fair-value loans $27.7M; principal outstanding $317.4M at 12/31/2025 across 15 loans; $366.4M as of 02/25/2026 across 15 loans
- Capital structure action: repurchased $13,000,000 of unsecured bonds during the quarter; $77,000,000 unsecured bonds remaining maturing May 2027
Capital Funding
- Unsecured bond repurchases: $13,000,000 during Q4 2025
- Remaining unsecured bonds: $77,000,000 with maturity May 2027; company evaluating refinancing options prior to maturity
- Liquidity referenced as a constraint/driver of deal pace: CEO stated ability to fund depends on cash balance and credit-facility capacity
Strategy & Ops
- Active nonaccrual management: 3 loans on nonaccrual with focus on receiving paydowns to redeploy into performing credits
- Continued liquidation/estate process for Private Company A (court/receiver distribution bottleneck); pending motion for additional $6,400,000 distribution
- Massachusetts dispensary collateral sales progression (Private Company K): two dispensaries under APA with court approval; pending CCC regulatory approval (3-4 months typically, may be longer/shorter); third dispensary awaiting final LOIs
- Justice Grown litigation/procedural milestones: one claim dismissed in New Jersey action; oral arguments on preliminary injunction appeal; ruling expected in coming months; loan matures 05/01/2026
Market Outlook
- No formal forward guidance for loan volumes/yields; however, Q&A discussed an implied near-term pace question: management said a ~$100,000,000 per quarter origination/deployment pace is not currently sustainable given credit-facility/cash capacity (outside of possible nonaccrual proceeds)
Risks & Headwinds
- Underperformance/realized losses impact earnings and dividend tax treatment: two underperforming credits drove realized losses in 2025; 2025 dividends treated as return of capital; future treatment contingent on additional losses in 2026
- Nonaccrual and legal/liquidation process delays: Private Company A distributions constrained by receiver/court approvals (pace described as 'frustrated'); $6,800,000 distributed in 2025 and $6,400,000 pending motion
- Private Company K execution risk: CCC regulatory approval timing uncertainty; typical 3-4 months but can be longer; third dispensary timeline contingent on final LOIs
- Justice Grown uncertainty around appeal outcome and timing: no additional commentary beyond maturity (05/01/2026) and expectation of appeal ruling in coming months
- Cannabis sector deployment constraint: management stated 'bar is very, very high' for new cannabis loans; despite hoped regulatory approval, limited progress since August 2023 plus lack of equity capital and rising tax liabilities make deploying fresh capital difficult
- Deal pace capacity constraint: management indicated it does not have capacity to sustain ~$100M/quarter pace for the rest of 2026 under current conditions
Sentiment: MIXED
Note: This summary was synthesized by AI from the AFCG Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"AFCG reported revenue of $6.64M and a net income of $914k for the year ending December 31, 2025. The company's operating cash flow was negative at -$560k, and it faced substantial dividend payouts totaling approximately $3.39M, contributing to negative free cash flow. Total assets stand at $275.59M, with total liabilities of $100.03M, resulting in a solid equity position of $175.57M. However, the company is carrying a net debt of approximately $37.72M, raising concerns over leverage. The share price is currently at $2.62, representing a significant 58.74% decline over the past year. AFCG has consistently paid dividends, although its financial health is being pressured due to negative cash flows. The price target consensus is $16, suggesting potential undervaluation, yet the recent market performance indicates high volatility and investor skepticism."
Revenue Growth
Revenue growth is minimal, and the company has not shown significant progress.
Profitability
Net income is positive, indicating profitability, but future sustainability is uncertain.
Cash Flow Quality
Negative operating cash flow raises concerns about cash management and sustainability.
Leverage & Balance Sheet
While equity levels are decent, the net debt position suggests some leverage risk.
Shareholder Returns
Recent share price decline and significant dividend payments reduce shareholder return attractiveness.
Analyst Sentiment & Valuation
Recent price performance is poor, but analysts believe there may be upside potential based on price targets.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.